Strengths and prices
| Strength | Price per vial | Availability | Batch | |
|---|---|---|---|---|
| 5 mg | $40.00 | In stock | — |
Every vial carries its batch code and a QR that opens the certificate of analysis for that exact batch. No account is needed to read one.
What it is
CJC-1295 with DAC is a synthetic analogue of growth hormone releasing hormone (GHRH 1-29) with four amino-acid substitutions and a Drug Affinity Complex, a linker that binds the peptide to albumin.
Identity
| Type | Synthetic peptide (GHRH 1-29 analogue with DAC) |
|---|---|
| Molecular formula | C165H269N47O46 |
| Molecular weight | 3647.2 g/mol |
| CAS number | 446262-90-4 |
| PubChem CID | 91971820 |
CJC-1295 with DAC is a synthetic peptide of 30 residues: GHRH(1-29) with four substitutions (D-alanine at position 2, glutamine at 8, alanine at 15 and leucine at 27), followed by a C-terminal lysine amide whose side chain carries a 3-maleimidopropionyl group. The sequence is Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(maleimidopropionyl)-NH2. Molecular formula C165H269N47O46, molecular weight 3647.2 g/mol (PubChem CID 91971820, CAS 446262-90-4). The maleimide is the reactive part of the Drug Affinity Complex: it forms a covalent bond with the free thiol of cysteine 34 on albumin. Mass spectrometry confirms the full mass with the linker attached, which also distinguishes it from the version sold without the linker, and HPLC reports purity. It is supplied as a white lyophilized powder in a sealed vial.
What the published research covers
A 2006 study in healthy adults measured growth hormone and IGF-1 over the days after administration. Clinical development was not continued.
CJC-1295 was developed in the early 2000s by ConjuChem, a Montreal company, as a long-acting analogue of growth hormone releasing hormone. Native GHRH has a very short half-life in circulation. The developers took the active fragment GHRH(1-29), made four amino-acid substitutions, and added a reactive maleimide group on a C-terminal lysine so that the peptide bonds to circulating albumin. The albumin conjugates resisted dipeptidyl peptidase-IV in vitro, and in rats the best of three candidates, CJC-1295, produced four times the growth hormone response of unmodified GHRH(1-29) over two hours and was still present in plasma after 72 hours (Jetté, 2005).
In mice lacking the GHRH gene, administration once a day for five weeks from one week of age gave normal body weight and length, with a smaller effect when the interval was 48 or 72 hours, and increased pituitary growth hormone mRNA (Alba, 2006). In healthy adults aged 21 to 61, two randomized, placebo-controlled, double-blind trials with ascending amounts measured pharmacokinetics and hormone levels: after a single administration, mean growth hormone rose 2- to 10-fold for six days or more and IGF-1 rose 1.5- to 3-fold for 9 to 11 days, with larger responses at larger amounts, and the estimated half-life was 5.8 to 8.1 days (Teichman, 2006). A study that sampled blood every 20 minutes overnight in healthy men found that growth hormone remained pulsatile a week after a single administration, with trough levels 7.5-fold higher and IGF-1 45 percent higher than before (Ionescu, 2006). A proteomic analysis of serum from 11 healthy men before and after administration reported changes in several proteins, including isoforms of apolipoprotein A1 and transthyretin (Sackmann-Sala, 2009).
The human data are small early-phase studies in healthy volunteers that measured hormone levels; no trial of a clinical outcome has been published, and clinical development was not continued. Several of the studies include the developer's scientists among their authors. Suppliers also use the name CJC-1295 for the same 29-residue peptide without the albumin-binding group, often called modified GRF(1-29); the published studies concern the version with the linker, and the mass on the certificate of analysis shows which a batch contains.
Regulatory status
Not approved by the FDA for any use. Supplied for laboratory research only.
Testing and documentation
Identity is confirmed by mass spectrometry and purity by HPLC. The certificate of analysis for the batch is reachable from the code on the vial.
Questions laboratories ask
- What strength is CJC-1295 with DAC offered in?
- Vials of 5 mg, as listed on the product page. The amount is on the vial label and on the certificate of analysis for the batch.
- Is this the same as CJC-1295 without DAC?
- No. CJC-1295 without DAC, often called modified GRF(1-29), has the same 29 amino acids but lacks the lysine and maleimide linker that binds albumin, so its mass is lower. The certificate of analysis for the batch states the measured mass.
- Is this an approved medicine?
- No. CJC-1295 was studied in early clinical trials, but it is not approved by the FDA for any use. This material is supplied for laboratory research only.
- How is a batch tested?
- By an independent laboratory: identity by mass spectrometry and purity by HPLC. The QR code on the vial opens the certificate of analysis for that exact batch; no account is needed to read it.
- Who can order, and how does it ship?
- Orders are accepted under the Research Use Agreement, reaffirmed with every order. Orders ship from Montana, the next business day when paid by card, to United States addresses only and not to freight forwarders.
References
- Jetté L et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. PubMed 15817669
- Teichman SL et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. PubMed 16352683
- Alba M et al. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology. Endocrinology and Metabolism. PubMed 16822960
- Ionescu M et al. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism. PubMed 17018654
- Sackmann-Sala L et al. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone and IGF Research. PubMed 19386527
How it ships
Ordering
Ordering needs an account. A retail account opens as soon as you request it and costs nothing. You pay by card at checkout, or by invoice before the order ships. A wholesale account is reviewed before it opens.
Research use only
This product is a research chemical sold solely for in-vitro laboratory research by qualified persons. It is not a drug, food, supplement or cosmetic, has not been evaluated by the FDA, and must not be administered to any person or animal. Read the full agreement